• The predictive power of in silico for mAbs

    MAbSilico provides innovative in silico methods to accelerate antibody development. Our unique computational technologies and expertise allow to select, characterize and patent your best lead.

  • Highlights

    Benefits of a predictive computational solutions

    Proprietary method, unique know-how

    Our expertise in protein-protein interactions and protein modelling to ensure optimized predictions

    Fee for

    services

    Full ownership and exclusive right for customer

    Fast data

    Delivery

    Prediction report within 2-4 weeks

    Secure your

    IP

    Deep characterization for high protection

    Flexible

    offers

    Either predictive in silico data or experimental validations using state-of-the art protein-protein interaction technologies (HTRF, biolayer interferometry…), or both

  • Our services

    We accelerate and secure the development of your antibody at early stage

    1

    MAbTarget

    Target identification

    2

    MAbSubstitute

    Lead identification and antibody repositionning

    3

    MAbTope

    Epitope mapping

    4

    MAbCross

    Cross reactivity forecasting

  • Focus on MAbTope

    The power of prediction of MAbSilico - Golimumab epitope on TNFα

  • Team

    Vincent Puard, PhD

    CEO

    10 years of international experience in academia and private business working with antibodies

    Astrid Musnier, PhD

    CSO

    10 years of international experience in research and academia. Expert in protein-protein interaction technologies, co-inventor of the methods

    Anne Poupon, PhD

    Scientific Advisor

    International expert of more than 20 years of research in bioinformatics leading to the invention of our methods. PI at CNRS and co-leader of the BIOS group at INRA Val de Loire

  • Partners

  • MAbSilico News

    MAbSilico and Synthelis sign a commercial agreement to promote a joint service offering. June 2018

    As of June 21, 2018, Synthelis and MAbSilico combine their know-how and thus capitalize on their respective technology in developing a joint offer through a commercial agreement, responding to the needs of their customers.

     

    This offer combines the cutting-edge expertise of two recognized players in their respective domain: MAbSilico with its in silico method to characterize antibodies at their early stage of development and Synthelis, for its cell-free patented technology.

    MAbSilico is talking at the 6th Antibody Industrial Symposium. June 2018

    The 6th Antibody Industrial Symposium 2018 (AIS2018) will be held the 25th and 26th of June 2018 in Montpellier, France. This congress, jointly organized by the scientific society LabEx MAbImprove and the industrial organization MabDesign, is part of the series of Industrial Symposia organized by MAbImprove since 2013 (Antibodies Biosimilars, MAbDosing, MAbDelivery, Current & Next Generation Antibody Formats, Antibody Drug Conjugates).

    MAbSilico is selected to be accelerated at Le Château. March 2018

    Le Château is an accelerating program for early stage startups.

    MAbSilico is talking at the Immunotherapies for Infectious Diseases Congress. December 2017

    The second edition of the Immunotherapies for Infectious Diseases Congress - I4ID, that will be held in Lyon (France) on December 10-11, 2018, this year dedicated to Host-Directed Therapies (HDT) to fight infectious diseases.

    MAbSilico is selected in the top 500 startups at the Hello Tomorrow Global Challenge. October 2017

    The Hello Tomorrow Challenge is the world’s biggest early-stage startup competition for science and deep technology startups. Each year, they identify the best projects of the Challenge to attend the Hello Tomorrow Summit in Paris, an invite-only event bringing together the people that will change the world using science and technology around top investors in each sector, industrial leaders (Airbus, Google[x], Carrefour, Merck, Air Liquide, Facebook, etc.), international media (Bloomberg, BBC, Wired, etc.) and influencers (in 2016, Mike Bloomberg, Emmanuel Macron, CTO of Meta, CEO of Unity Biotech, etc).

    MAbSilico is at the Next-Generation Antibodies and Protein Analysis. October 2017

    Catalyzed by VIB’s Technology Scouting team, the Tools and Technologies meetings focus on the front end of innovation and bring together key innovators in selected life sciences research fields. The Next-Generation Antibodies and Protein Analysis conference, in Ghent (Belgium), is set to make another world class meeting, bringing together an exciting selection of top speakers and newly emerged companies. In addition to great scientific and technology program, the conference will provide ample networking opportunities.

    MAbSilico received the "Bourse French Tech" from Bpifrance. October 2017

    MAbSilico is founded. September 2017

    We are happy to announce the incorporation of MAbSilico.

  • Contact Us

    Learn more about our services today.